a Department of Molecular Medicine and Medical Biotechnology , University of Naples "Federico II" , Napoli ( NA ), Italy.
b CEINGE - Biotecnologie Avanzate s.c. a.r.l ., Naples , Italy.
MAbs. 2018 Oct;10(7):1060-1072. doi: 10.1080/19420862.2018.1496772. Epub 2018 Aug 1.
Immune checkpoints are emerging as novel targets for cancer therapy, and antibodies against them have shown remarkable clinical efficacy with potential for combination treatments to achieve high therapeutic index. This work aims at providing a novel approach for the generation of several novel human immunomodulatory antibodies capable of binding their targets in their native conformation and useful for therapeutic applications. We performed a massive parallel screening of phage libraries by using for the first time activated human lymphocytes to generate large collections of single-chain variable fragments (scFvs) against 10 different immune checkpoints: LAG-3, PD-L1, PD-1, TIM3, BTLA, TIGIT, OX40, 4-1BB, CD27 and ICOS. By next-generation sequencing and bioinformatics analysis we ranked individual scFvs in each collection and identified those with the highest level of enrichment. As a proof of concept of the quality/potency of the binders identified by this approach, human IgGs from three of these collections (i.e., PD-1, PD-L1 and LAG-3) were generated and shown to have comparable or better binding affinity and biological activity than the clinically validated anti-PD-1 mAb nivolumab. The repertoires generated in this work represent a convenient source of agonistic or antagonistic antibodies against the 'Checkpoint Immunome' for preclinical screening and clinical implementation of optimized treatments.
免疫检查点正在成为癌症治疗的新靶点,针对这些靶点的抗体显示出显著的临床疗效,具有与联合治疗相结合以实现高治疗指数的潜力。本工作旨在提供一种新方法,用于产生几种能够以天然构象结合其靶标的新型人免疫调节抗体,这些抗体可用于治疗应用。我们首次使用激活的人淋巴细胞对噬菌体文库进行了大规模平行筛选,以生成针对 10 种不同免疫检查点的大量单链可变片段(scFvs)的集合:LAG-3、PD-L1、PD-1、TIM3、BTLA、TIGIT、OX40、4-1BB、CD27 和 ICOS。通过下一代测序和生物信息学分析,我们对每个集合中的单个 scFv 进行了排序,并确定了那些富集程度最高的 scFv。作为通过这种方法鉴定的结合物的质量/效力的概念验证,从这三个集合(即 PD-1、PD-L1 和 LAG-3)中的三个集合中生成了人 IgG,并证明它们具有可比或更好的结合亲和力和生物学活性比临床验证的抗 PD-1 mAb nivolumab。本工作中生成的文库代表了针对“检查点免疫组”的激动剂或拮抗剂抗体的方便来源,可用于优化治疗的临床前筛选和临床实施。